Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Common Stock |
6.8M |
$129M |
$19.00 |
Jun 28, 2021 |
Direct |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Common Stock |
2.1M |
$39.9M |
$19.00 |
Jun 28, 2021 |
By Versant Vantage I, L.P. |
Century Therapeutics, Inc. |
10%+ Owner |
Common Stock |
11.5M |
$17.1M |
$1.49 |
Aug 9, 2022 |
Direct |
LENZ Therapeutics, Inc. |
10%+ Owner |
Common Stock |
2.1M |
$8.57M |
$4.08 |
Mar 21, 2024 |
Direct |
LENZ Therapeutics, Inc. |
10%+ Owner |
Common Stock |
842K |
$3.44M |
$4.08 |
Mar 21, 2024 |
Indirect |
Tempest Therapeutics, Inc. |
10%+ Owner |
Common Stock |
2.12M |
$2.33M |
$1.10 |
Aug 8, 2024 |
Indirect |
Century Therapeutics, Inc. |
10%+ Owner |
Common Stock |
714K |
$1.06M |
$1.49 |
Aug 9, 2022 |
Indirect |
Tempest Therapeutics, Inc. |
10%+ Owner |
Common Stock |
210K |
$231K |
$1.10 |
Aug 12, 2024 |
Direct |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series B Preferred Stock |
1.74M |
|
|
Apr 9, 2024 |
Direct |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series A-1 Preferred Stock |
1.42M |
|
|
Apr 9, 2024 |
Direct |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series C Preferred Stock |
710K |
|
|
Apr 9, 2024 |
Indirect |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series B Preferred Stock |
435K |
|
|
Apr 9, 2024 |
Indirect |
Contineum Therapeutics, Inc. |
10%+ Owner |
Class A Common Stock |
376K |
|
|
Apr 9, 2024 |
Direct |
Contineum Therapeutics, Inc. |
10%+ Owner |
Class A Common Stock |
148K |
|
|
Apr 9, 2024 |
Indirect |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series A Preferred Stock |
9.25K |
|
|
Apr 9, 2024 |
Indirect |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series A convertible preferred stock |
0 |
|
|
Jun 28, 2021 |
Direct |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
Jun 28, 2021 |
By Versant Vantage I, L.P. |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
Jun 28, 2021 |
Direct |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Series C convertible preferred stock |
0 |
|
|
Jun 28, 2021 |
By Versant Vantage I, L.P. |
Oyster Point Pharma, Inc. |
10%+ Owner |
Common Stock |
0 |
|
$11.20 |
Jan 3, 2023 |
Direct |
Oyster Point Pharma, Inc. |
10%+ Owner |
Common Stock |
0 |
|
$11.20 |
Jan 3, 2023 |
Indirect |